Report of Foreign Issuer (6-k)
February 17 2017 - 11:58AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
17 February
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the '
Company
')
Conditional Share Awards
On 15
February 2017 the Company granted conditional awards to the below
Executive Directors and Persons Discharging Managerial
Responsibilities. The awards have been granted in accordance
with the rules of the GlaxoSmithKline 2009 Deferred Annual Bonus
Plan (DABP) which was approved by shareholders on 20 May
2009.
Participants
are required to defer 25% of any bonus earned into Ordinary Shares
or ADSs and may be eligible to choose to invest up to an additional
25% (i.e. up to a maximum of 50%) (Deferred Bonus
Award).
The
Company will match the Deferred Bonus Award up to one-for-one
depending on the achievement of performance targets (Matching
Award). Details of the performance measures will be confirmed later
in the year following shareholder approval of the Remuneration
Policy at the AGM on 4 May 2017.
The
performance period for the awards is the three financial years from
1 January 2017 to 31 December 2019.
The
awards of deferred and matching shares have been granted as
conditional awards over ADSs for US pre-tax participants and as
nil-cost options over Ordinary Shares for all other
participants.
The
vesting date for these conditional awards will be the later of the
date, following the end of the three year performance period, on
which the Remuneration Committee determines the extent to which the
performance measures have been achieved, the third anniversary of
the Award Date or such other later date as determined by the
Remuneration Committee.
The
amounts shown below are the maximum amounts payable (exclusive of
dividend reinvestment during the performance period). The
actual pay-out will be determined by performance over the period.
Progress against targets will be reported in the Company's Annual
Report yearly.
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Sir Andrew Witty
|
b)
|
Position/status
|
Chief Executive Officer
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
As Sir Andrew is retiring from the Company on 31 March 2017 he is
not eligible for a matching award.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
34,353
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a(single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
CEO Designate
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
31,945
|
|
|
£15.770
|
31,945
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
63,890
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
16,633
|
|
|
£15.770
|
16,633
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
33,266
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr L Debruyne
|
b)
|
Position/status
|
President, Global Vaccines
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
27,957
|
|
|
£15.770
|
27,957
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
55,914
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S Dingemans
|
b)
|
Position/status
|
Chief Financial Officer
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
29,022
|
|
|
£15.770
|
29,022
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
58,044
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
10,513
|
|
|
£15.770
|
10,513
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
21,026
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S A Hussain
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
29,059
|
|
|
£15.770
|
29,059
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
58,118
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr B McNamara
|
b)
|
Position/status
|
CEO, Consumer Healthcare
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of ADSs (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject to performance
measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.110
|
6,128
|
|
|
$40.110
|
6,128
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a (single transaction)
|
Aggregated
volume Price
|
12,256
$40.110
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
13,231
|
|
|
£15.770
|
13,231
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
26,462
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr M M Slaoui
|
b)
|
Position/status
|
Chairman, Global Vaccines
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
As Dr Slaoui is retiring from the Company on 30 June 2017 he is not
eligible for a matching award.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.110
|
10,760
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a (single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
SVP, Human Resources
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
19,916
|
|
|
£15.770
|
19,916
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
39,832
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr P C Thomson
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
6,269
|
|
|
£15.770
|
6,269
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
12,538
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D E Troy
|
b)
|
Position/status
|
SVP & General Counsel
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of ADSs (under the GlaxoSmithKline
2009 Deferred Annual Bonus Plan) subject to performance
measures
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.110
|
13,005
|
|
|
$40.110
|
13,005
|
|
|
|
|
|
d)
|
Aggregated
information
|
n/a (single transaction)
|
Aggregated
volume Price
|
26,010
$40.110
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, R&D
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
1)
Deferred Bonus Award conditional award of Ordinary Shares (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Matching Award conditional award of Ordinary Shares (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.770
|
21,632
|
|
|
£15.770
|
21,632
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
Aggregated
volume Price
|
43,264
£15.770
|
e)
|
Date
of the transaction
|
2017-02-15
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
17, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024